VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Wierda on Ibrutinib Resistance in CLL

William G. Wierda, MD, PhD
Published: Tuesday, May 26, 2015



William G. Wierda, MD, PhD, medical director, Leukemia Center, The University of Texas MD Anderson Cancer Center, discusses resistance to ibrutinib in patients with chronic lymphocytic leukemia (CLL).

Not many patients are resistant to ibrutinib, Wierda explains. However, approximately 30-40% of patients who develop resistance have Richter’s transformation, and will likely require more aggressive treatment. Other patients may discontinue treatment due to toxicity.

However, BTK and PLCG2 mutations can occur, which render resistance to ibrutinib. Regarding standard clinical use of the drug, Wierda says there is no need to monitor for these mutations nor adjust treatment for it, though data should be collected.



William G. Wierda, MD, PhD, medical director, Leukemia Center, The University of Texas MD Anderson Cancer Center, discusses resistance to ibrutinib in patients with chronic lymphocytic leukemia (CLL).

Not many patients are resistant to ibrutinib, Wierda explains. However, approximately 30-40% of patients who develop resistance have Richter’s transformation, and will likely require more aggressive treatment. Other patients may discontinue treatment due to toxicity.

However, BTK and PLCG2 mutations can occur, which render resistance to ibrutinib. Regarding standard clinical use of the drug, Wierda says there is no need to monitor for these mutations nor adjust treatment for it, though data should be collected.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Emerging Treatment Options for Patients With High-Risk AMLMay 31, 20181.0
Oncology Briefings™: Updates in Pediatric Hepatic Veno-Occlusive Disease: Integrating Novel Therapeutic Strategies to Overcome Post-Transplant ObstaclesMay 31, 20181.0
Publication Bottom Border
Border Publication
x